Dickinson E T, O'Connor R E, Megargel R
Albany Medical College, NY.
Del Med J. 1992 Nov;64(11):679-83.
The use of prehospital nebulized beta-agonists has become widespread, and their safety and efficacy has been documented. Our purpose was to study their broadened use and determine their effectiveness in specific sub-sets of wheezing patients. We conducted a six and one-half month prospective study to determine the benefit of nebulized albuterol treatments on a variety of wheezing patients whose chief complaint to paramedics was shortness of breath. Sixty-two patients were enrolled in the study and were subdivided into four groups based on patient history; asthma, COPD, asthma & COPD (A/C), and non-Asthma/non-COPD (NANC). The effectiveness of the treatment was evaluated objectively by peak expiratory flow rates (PEFR) obtained before and immediately after treatment and subjectively by the patients' evaluation of their own dyspnea. Changes in PEFR were subjected to analysis by a paired T-test. Albuterol was effective in increasing the PEFR in patients with asthma, COPD and NANC. Patients with both asthma and COPD did not demonstrate increased PEFR after treatment. The majority of all patients were subjectively improved after nebulized albuterol treatments. We conclude that aerosolized albuterol is safe and effective in the prehospital treatment of patients complaining of dyspnea who are wheezing.
院前雾化吸入β-受体激动剂的使用已广泛普及，其安全性和有效性也已得到证实。我们的目的是研究其更广泛的用途，并确定其在喘息患者特定亚组中的有效性。我们进行了一项为期六个半月的前瞻性研究，以确定雾化吸入沙丁胺醇治疗对各种以呼吸急促为主诉呼叫护理人员的喘息患者的益处。62名患者参与了该研究，并根据病史分为四组：哮喘组、慢性阻塞性肺疾病（COPD）组、哮喘合并COPD（A/C）组和非哮喘/非COPD（NANC）组。通过治疗前和治疗后立即测得的呼气峰值流速（PEFR）客观评估治疗效果，并通过患者对自身呼吸困难的评估主观评估治疗效果。对PEFR的变化进行配对T检验分析。沙丁胺醇对哮喘、COPD和NANC患者增加PEFR有效。哮喘合并COPD患者治疗后未显示PEFR增加。所有患者中大多数在雾化吸入沙丁胺醇治疗后主观症状有所改善。我们得出结论，雾化吸入沙丁胺醇在院前治疗喘息且主诉呼吸困难的患者中是安全有效的。
